Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
about
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Pharmacology and pharmacokinetics of imatinib in pediatric patients.Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
P2860
Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@en
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@nl
type
label
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@en
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@nl
prefLabel
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@en
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@nl
P2093
P2860
P1476
Should therapeutic drug monito ...... smethyl-imatinib be developed?
@en
P2093
Françoise Huguet
Laurence Malard
Peggy Gandia
Thierry Lafont
P2860
P2888
P304
P356
10.1007/S00280-012-2035-3
P577
2012-11-27T00:00:00Z
P6179
1007964107